Sangamo Biosciences, Inc.

Sangamo Therapeutics, Inc.

Ospedale San Raffaele S.r.l.

The University of Texas System

The Children's Hospital of Philadelphia

City of Hope

University of Southern California

Fondazione Telethon

Sigma-aldvich Co. LLC

Whitehead Institute for Biomedical Research

Sigma-aldrich Co. LLC

Philip D Gregory

Fyodor Urnov

Michael C Holmes

David Paschon

Edward J Rebar

Lei Zhang

Jeffrey C Miller

Andreas Reik

Siyuan Tan

H Steve Zhang

Russell DeKelver

Luigi Naldini

Trevor Collingwood

Pietro Genovese

Maria Chiara Bonini

Phillip Tam

Gregory J Cost

Xiangdong Meng

Matthew C Mendel

Andrew Snowden

Michael C Jensen

Katherine A High

Dmitry Y Guschin

Laurence J N Cooper

Dale Ando

Elizabeth J Wolffe, Legal Representative

Elena Provasi

Casey Christopher Case

Alan P Wolffe

Albert Lai

Zulma Magnani

Hojun Li

Sara Mastaglio

Russell Dekelver

Rudolf Jaenisch

Jianbin Wang

Anthony Conway

Gregory D Davis

Angelo Leone Lombardo

Paula M Cannon

Steven Froelich

Hiroki Torikai

Laurence Jn Cooper

Frank Soldner

Xiaoxia Cui

Shuyuan Yao

Russell DeKeiver

Elizabeth Wolffe

Dirk Hockemeyer

Steve H Zhang

Edward J Weinstein

Dmitry Guschin

Rudolf Jaenish

Laurence JN Cooper

Steve Zhang H

Laurence J Cooper

Sean M Brennan

Disclosed herein are methods and compositions for inactivation of the human glucocorticoid receptor (GR) gene by targeted cleavage of genomic DNA encoding the GR. Such methods and compositions are useful, for example, in therapeutic applications which require retention of immune function during glucocorticoid treatment.

Method of inactivating a glucocorticoid receptor gene in an isolated cell

Disclosed herein are polypeptides, polynucleotides encoding, cells and organisms comprising novel DNA-binding domains, including TALE DNA-binding domains. Also disclosed are methods of using these novel DNA-binding domains for modulation of gene expression and/or genomic editing of endogenous cellular sequences.

DNA-binding proteins and uses thereof

Disclosed herein are methods and compositions for targeted integration of an exogenous sequence into the human PPP1R12C locus, for example, for expression of a polypeptide of interest.

Targeted integration into the PPP1R12C locus

Methods and compositions for a genetic disease are provided.

Methods and compositions for treatment of a genetic condition

Disclosed herein are methods and compositions for inactivating TCR genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided. Disclosed herein are also methods and compositions for expressing a functional exogenous TCR in the absence of endogenous TCR expression in T lymphocytes, including lymphocytes with a central memory phenotype. Polynucleotides encoding exogenous TCR, vectors comprising polynucleotides encoding exogenous TCR and cells comprising polynucleotides encoding exogenous TCR and/or cells comprising exogenous TCR are also provided.

Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases

Disclosed herein are methods and compositions for modulating expression of a PD1 gene.

Methods and compositions for modulating PD1

Methods and compositions for modifying T-cells in which PD1 and/or CTLA-4 is repressed and/or inactivated using fusion proteins such as artificial transcription factors and nucleases.

T cell modifying compounds and uses thereof

Disclosed herein are methods and compositions for modifying TCR genes, using nucleases (zinc finger nucleases or TAL nucleases) to modify TCR genes.

Isolated human cell with an inactivated glucocorticoid receptor gene

Disclosed herein are methods and compositions for modulating the expression of a HLA locus or for selectively deleting or manipulating a HLA locus or HLA regulator.

Methods and compositions for modification of a HLA locus

Disclosed herein are methods and compositions for treating trinucleotide repeat disorders.

Methods and compositions for treating trinucleotide repeat disorders

The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a hematopoietic cell.

Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells

Growing community of inventors

Richmond, CA, United States of America

Philip D Gregory